Vanda Pharmaceuticals logo

Vanda PharmaceuticalsNASDAQ: VNDA

Profile

Sector:

Healthcare

Industry:

Biotechnology

Country:

United States

IPO:

12 April 2006

Next earnings report:

07 February 2025

Last dividends:

N/A

Next dividends:

N/A
$296.79 M
-70%vs. 3y high
59%vs. sector
-vs. 3y high
-vs. sector
-72%vs. 3y high
27%vs. sector
-58%vs. 3y high
33%vs. sector

Price

after hours | Fri, 22 Nov 2024 23:42:04 GMT
$5.09+$0.14(+2.83%)

Dividend

No data over the past 3 years
$47.65 M$52.25 M
$47.65 M-$5.32 M

Analysts recommendations

Institutional Ownership

VNDA Latest News

Vanda Pharmaceuticals Announces Participation at November 2024 Investor Conferences
prnewswire.com12 November 2024 Sentiment: POSITIVE

WASHINGTON , Nov. 12, 2024 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) today announced that the company will participate in the following upcoming investor conferences in November 2024: The Stifel 2024 Healthcare Conference on Tuesday, November 19, 2024. A corporate presentation is scheduled for 9:45 a.m.

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Vanda Pharmaceuticals Inc. - VNDA
accesswire.com04 November 2024 Sentiment: NEGATIVE

NEW YORK, NY / ACCESSWIRE / November 4, 2024 / Pomerantz LLP is investigating claims on behalf of investors of Vanda Pharmaceuticals Inc. ("Vanda" or the "Company") (NASDAQ:VNDA). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext.

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Vanda Pharmaceuticals Inc. - VNDA
prnewswire.com02 November 2024 Sentiment: NEGATIVE

NEW YORK , Nov. 2, 2024 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Vanda Pharmaceuticals Inc. ("Vanda" or the "Company") (NASDAQ: VNDA). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext.

Over 200% Stock Upside - Vanda Pharmaceuticals Undervalued With Robust Portfolio And Pipeline: Analyst
benzinga.com01 November 2024 Sentiment: POSITIVE

HC Wainwright initiated coverage on Vanda Pharmaceuticals, Inc. VNDA, a commercial-stage biopharmaceutical firm primarily focusing on neurological and neuropsychiatry disorders.

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Vanda Pharmaceuticals Inc. - VNDA
accesswire.com31 October 2024 Sentiment: NEGATIVE

NEW YORK, NY / ACCESSWIRE / October 31, 2024 / Pomerantz LLP is investigating claims on behalf of investors of Vanda Pharmaceuticals Inc. ("Vanda" or the "Company") (NASDAQ:VNDA). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext.

Vanda Pharmaceuticals to Announce Third Quarter 2024 Financial Results on November 6, 2024
prnewswire.com30 October 2024 Sentiment: POSITIVE

Conference Call and Webcast to Follow WASHINGTON , Oct. 30, 2024 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) today announced it will release results for the third quarter 2024 on Wednesday, November 6, 2024, after the market closes. Vanda will host a conference call at 4:30 PM ET on Wednesday, November 6, 2024, during which management will discuss the third quarter 2024 financial results and other corporate activities.

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Vanda Pharmaceuticals Inc. - VNDA
accesswire.com27 October 2024 Sentiment: NEGATIVE

NEW YORK, NY / ACCESSWIRE / October 27, 2024 / Pomerantz LLP is investigating claims on behalf of investors of Vanda Pharmaceuticals Inc. ("Vanda" or the "Company") (NASDAQ:VNDA). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext.

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Vanda Pharmaceuticals Inc. - VNDA
prnewswire.com25 October 2024 Sentiment: NEGATIVE

NEW YORK , Oct. 25, 2024 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Vanda Pharmaceuticals Inc. ("Vanda" or the "Company") (NASDAQ: VNDA). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext.

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Vanda Pharmaceuticals Inc. - VNDA
accesswire.com19 October 2024 Sentiment: NEGATIVE

NEW YORK, NY / ACCESSWIRE / October 19, 2024 / Pomerantz LLP is investigating claims on behalf of investors of Vanda Pharmaceuticals Inc. ("Vanda" or the "Company") (NASDAQ:VNDA). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext.

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Vanda Pharmaceuticals Inc. - VNDA
prnewswire.com17 October 2024 Sentiment: NEGATIVE

NEW YORK , Oct. 17, 2024 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of  Vanda Pharmaceuticals Inc. ("Vanda" or the "Company") (NASDAQ: VNDA).  Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext.

What type of business is Vanda Pharmaceuticals?

Vanda Pharmaceuticals Inc. is an American biopharmaceutical company headquartered in Washington, D.C., developing and commercializing innovative drugs for the treatment of neurological disorders. It was founded in 2003. Currently, the company's product portfolio includes the following products: HETLIOZ and Fanapt. In addition, Vanda Pharmaceuticals Inc. is developing a range of medications, including: HETLIOZ for the treatment of disorders related to changing time zones and Smith-Magenis syndrome, Fanapt for the treatment of bipolar disorder, Tradipitant for the treatment of atopic dermatitis, gastroparesis, and motion sickness, VTR-297 for the treatment of hematologic malignancies and with potential use in the treatment of several oncological diseases, among others.

What sector is Vanda Pharmaceuticals in?

Vanda Pharmaceuticals is in the Healthcare sector

What industry is Vanda Pharmaceuticals in?

Vanda Pharmaceuticals is in the Biotechnology industry

What country is Vanda Pharmaceuticals from?

Vanda Pharmaceuticals is headquartered in United States

When did Vanda Pharmaceuticals go public?

Vanda Pharmaceuticals initial public offering (IPO) was on 12 April 2006

What is Vanda Pharmaceuticals website?

https://www.vandapharma.com

Is Vanda Pharmaceuticals in the S&P 500?

No, Vanda Pharmaceuticals is not included in the S&P 500 index

Is Vanda Pharmaceuticals in the NASDAQ 100?

No, Vanda Pharmaceuticals is not included in the NASDAQ 100 index

Is Vanda Pharmaceuticals in the Dow Jones?

No, Vanda Pharmaceuticals is not included in the Dow Jones index

When was Vanda Pharmaceuticals the previous earnings report?

No data

When does Vanda Pharmaceuticals earnings report?

The next expected earnings date for Vanda Pharmaceuticals is 07 February 2025